Stream Link: https://globalmeet.webcasts.com/starthere.jsp?ei=1668867&tp_key=98f9ca8b9e
A PTCE encore virtual symposium affiliated with the 2024 HOPA Annual Conference.
Program Description
Recognizing the different phases of chronic myeloid leukemia (CML) is an important element of risk stratification and influences treatment selection. As the central goal of CML treatment is preventing progression to the accelerated or blast phase, oncology pharmacists must understand the expanding frontline treatment arsenal. This program will focus on BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) and present clinical considerations for oncology pharmacists involved in treatment selection and evaluating patient response to treatment. Panelists will present patient cases that examine strategies for managing TKI therapies for patients with advanced phase CML or inadequate treatment response. As these medications are oral and self-administered, practical counseling points to optimize adherence and appropriately manage adverse effects will also be discussed.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 23, 2024
Expiration date: July 23, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Provide guidance for the assessment and management of chronic myeloid leukemia (CML) based on BCR::ABL1 mutation status
- Construct individualized treatment plans that address the unique needs of patients with CML, including the selection of appropriate drug therapies
- Employ guidance on medication adjustments, supportive care measures, and patient education to optimize adherence and overall treatment outcomes in patients with CML
Peter Campbell, PharmD, MBA, BCOP
Lead Clinical Pharmacy Manager
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
New York, New York
Jordan Snyder, PharmD, BCOP
Clinical Hematology Pharmacist
University of Kansas Health System
Kansas City, Kansas
Benyam Muluneh, PharmD, BCOP, CPP
Assistant Professor
Division of Pharmacotherapy & Experimental Therapeutics
University of North Carolina Eshelman School of Pharmacy
Associate Member, Cancer Prevention and Control Program
University of North Carolina Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-112-L01-P. The activity is available for CE credit through July 23, 2024.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Benyam Muluneh, PharmD, BCOP, CPP, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: NCI
Consultant: Servier
Stock/shareholder: Novartis (spouse)
Peter Campbell, PharmD, MBA, BCOP; and Jordan Snyder, PharmD, BCOP, have no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy L. Morris, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Daphne Davis, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Former employee: GSK
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms